ABSTRACT
Coronavirus disease 2019 (COVID-19) has resulted in considerable morbidity and mortality worldwide since December 2019. Diseases such as diabetes, hypertension, cardiovascular and pulmonary diseases are common comorbidities in COVID-19 patients and have been correlated with increased disease severity. Comorbidities lead the COVID-19 patient into a vicious infectious circle and are substantially associated with significant morbidity and mortality. This study was aimed to estimate prevalence of comorbidities in severe category of COVID survivors and non survivors. More than 90% patients with multiple comorbidities admitted to ICU did not survive compared to those with one or two comorbidities. Diabetes followed by hypertension was the most common comorbidity in these patients. Thus comorbid individuals must adopt vigilant preventive measures including vaccination and they require intensive management for better outcome.
ABSTRACT
Biopharmaceutical drugs or biologicals have become an essential part of modern pharmacotherapy. Biosimilars or similar biologics have been defined as drugs that have shown to have comparable quality, safety and efficacy to the original biopharmaceutical drugs. The past decade has seen a significant increase in interest in these products from the biotechnology industry. Major developments in order to establish a regulatory path for approval of these products have taken place . In order to understand how the different quality attributes of a biosimilar impact its safety and efficacy we need further efforts. India is globally regarded to have great potential for development and commercialization of biosimilars.